Sorafenib (BAY 43-9006): review of clinical development.

Abstract

Sorafenib (BAY 43-9006) is a novel oral bis-aryl urea compound originally developed as an inhibitor to RAF kinase for its anti-proliferative property. It also inhibits receptor tyrosine kinases of multiple pro-angiogenic factors such as VEGFR-2/3, Flt-3/ and PDGFR-beta. The combination of both its anti-proliferative and anti-angiogenic properties makes… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.